Although those researches have demonstrated that PR-negative status contributes to worse outcome for IBC, the difference of prognosis between ER+/PR− phenotype and ER+/PR+ phenotype is still unknown and needed to be further verified because worse outcome of PR-negative cohort mainly resulted from patients with triple-negative IBC in their study. This evidence concerns the gene ESR1 and inflammatory breast carcinoma.